Provigil Generic Exclusivity Dispute Keeps Lawyers Up At Night
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva dropped its suit when FDA conceded the firm has 180-day marketing exclusivity for generic Provigil; Mylan then sued the agency claiming Teva lost its exclusivity rights with its acquisition of Cephalon.